Efficacy of a New Commercial Vaccine Against Clostridioides difficile and Clostridium perfringens Type A for Recurrent Swine Neonatal Diarrhea Under Field Conditions
- PMID: 40362015
- PMCID: PMC12070884
- DOI: 10.3390/ani15091200
Efficacy of a New Commercial Vaccine Against Clostridioides difficile and Clostridium perfringens Type A for Recurrent Swine Neonatal Diarrhea Under Field Conditions
Abstract
Neonatal diarrhea causes significant economic losses in swine production by reducing average daily weight gain (ADWG) and increasing piglet mortality, with Clostridioides difficile (CD) and Clostridium perfringens type A (CPA) being the most common causes. The aim of this study was to evaluate the efficacy of a new commercial vaccine against these agents to minimize diarrhea, pre-weaning mortality, and its negative consequences on weight performance in suckling piglets under field conditions. The study consisted of two randomized, double-blind, negative-controlled field trials (Study A and B) focusing on clinically healthy pregnant sows from commercial pig farms experiencing recurrent neonatal diarrhea. In the meta-analysis of both farms, the control group showed lower performance compared to the vaccine group (least squares means differences) for ADWG (-14.5 g/day, p < 0.001), body weight (-0.33 kg, p < 0.001), and underweight piglets at weaning (6.94%, p = 0.011). The number of piglets with diarrhea (9.76%, p < 0.001) and the percentage of piglets treated with antibiotics for diarrhea (6.09%, p = 0.016) were lower in vaccinated animals compared to controls. No significant differences in pre-weaning mortality were observed. The results of this study suggest that the new commercial vaccine against CD and CPA reduces the incidence of neonatal diarrhea and the associated use of antibiotics, while positively impacts the growth performance of suckling piglets.
Keywords: Clostridioides difficile; Clostridium perfringens type A; antimicrobial drug use; clinical trial; neonatal diarrhea; swine; vaccine efficacy; weight performance.
Conflict of interest statement
The authors A.P.A., G.P.F., M.B., O.B.-M. and X.G. are employees of HIPRA and HIPRA Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Non-toxigenic strain of Clostridioides difficile Z31 reduces the occurrence of C. difficile infection (CDI) in one-day-old piglets on a commercial pig farm.Vet Microbiol. 2019 Apr;231:1-6. doi: 10.1016/j.vetmic.2019.02.026. Epub 2019 Feb 20. Vet Microbiol. 2019. PMID: 30955794
-
Antimicrobial resistance- and pathogen patterns in the fecal microbiota of sows and their offspring in German commercial pig farms.PLoS One. 2023 Aug 24;18(8):e0290554. doi: 10.1371/journal.pone.0290554. eCollection 2023. PLoS One. 2023. PMID: 37616234 Free PMC article.
-
Administration of non-pathogenic isolates of Escherichia coli and Clostridium perfringens type A to piglets in a herd affected with a high incidence of neonatal diarrhoea.Animal. 2017 Apr;11(4):670-676. doi: 10.1017/S1751731116001804. Epub 2016 Aug 30. Animal. 2017. PMID: 27574018
-
An investigation into the association between cpb2-encoding Clostridium perfringens type A and diarrhea in neonatal piglets.Can J Vet Res. 2013 Jan;77(1):45-53. Can J Vet Res. 2013. PMID: 23814355 Free PMC article.
-
Clostridial diarrheas in piglets: A review.Vet Microbiol. 2023 May;280:109691. doi: 10.1016/j.vetmic.2023.109691. Epub 2023 Feb 23. Vet Microbiol. 2023. PMID: 36870204 Review.
References
-
- Thomson J.R., Friendship R.M. Digestive System. In: Zimmerman J.J., Karriker L.A., Ramirez A., Schwartz K.J., Stevenson G.W., editors. Diseases of Swine. Wiley-Blackwell; Chichester, UK: 2012. pp. 216–218. - DOI
Grants and funding
LinkOut - more resources
Full Text Sources